FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150
Vilon is a short synthetic dipeptide composed of lysine bound to glutamic acid (Lys-Glu).
Vilon is considered a thymic peptide analogue, meaning it mimics biological activity associated with peptides produced by the thymus gland, an organ essential to immune system development.
Like other bioregulatory peptides, Vilon has been studied for its ability to regulate protein synthesis and normalize cellular homeostasis, particularly in tissues affected by stress, aging, or immune dysfunction.
While Vilon is not approved for medical use outside research settings, its small molecular structure enables high bioavailability and cell membrane permeability, characteristics that have made it an important subject in peptide-based therapy research.
Vilon shows immunomodulatory properties, particularly its effects on thymus-dependent immune pathways.
In an in vitro study using human monocytic THP-1 cells, Vilon treatment resulted in [1]:
In Type 1 diabetes patients, administering Vilon resulted in [2]:
Vilon has been investigated within the field of bioregulatory peptide research for its potential role in cellular repair, longevity regulation, and tissue regeneration.
A case series examined 250 adults aged 65–87 with chronic periodontitis along with type II diabetes, atherosclerosis, and other cardiovascular diseases. Subjects received 10–20 µg daily submucosally for 5–10 days. The treatment significantly improved immune, oxidative stress, and coagulation parameters. Vilon treatment also reduced periodontal pocket depths by 1.2 Ramfjord index points and papillary marginal alveolar index by 10 times. These benefits, however, happened to a lesser degree in younger people with chronic periodontitis [3].
Age-associated declines in phosphorylated CREB (pCREB) reduce levels of arylalkylamine N-acetyltransferase (AANAT), contributing to age-related declines in melatonin, circadian rhythm, and sleep disruption.
Rat pinealocytes were treated with either control (no treatment), norepinephrine (NE) 1 µg/ml (positive control), or peptide-treated cultures (epithalone or Vilon) at 100 ng/ml. Subsequently, cultures were incubated for up to 3 hours at 36.7°C in 5% CO2 [4].
Results showed that Vilon:
Vilon peptide transiently enhances early transcriptional activation (pCREB) and enzyme induction (AANAT) in pinealocytes, suggesting it plays a regulatory role in stimulating melatonin synthesis at the initial phase of the signaling cascade.
Aging is often associated with increased chromatin condensation (heterochromatinization), which suppresses gene expression.
Another cell study investigated the effects of Vilon on chromatin organization in cultured lymphocytes obtained from elderly individuals [5]. The results demonstrated that Vilon loosened chromatin both globally and in the nucleolus, restoring access to genes silenced during aging.
Vilon plays an apoptoregulatory role, helping to protect somewhat damaged healthy cells. However, in cancer cells, Vilon seems to increase apoptotic cell death, which can help prevent further cancer progression.
In a cell study, administration of Vilon administered to rat spleen lymphocytes post-radiation induced significantly less apoptosis [6]. To date, the exact mechanisms by which apoptosis is inhibited has not been elucidated.
In rats transplanted with carcinoma, Vilon stimulated apoptosis in both young and old rats, suggesting that instead of protecting damaged cells, Vilon plays a more apoptoregulatory role [7].
Because dysregulated apoptosis is a hallmark feature of carcinogenesis, some studies have explored Vilon’s effects in oncological research settings.
Early experimental reports from Russian investigators suggest that Vilon could serve as an adjuvant to cancer therapy, resulting in [8]:
However, such studies remain experimental, and no clinical evidence currently supports Vilon for use in oncology.
Vilon’s role in apoptoregulation continues to be a subject of research in the broader field of cellular homeostasis and peptide-based cytoprotection.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
— Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Vilon is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
